IPSEN (OTCMKTS:IPSEY) Shares Gap Up – What’s Next?

IPSEN (OTCMKTS:IPSEY)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $43.85, but opened at $46.50. IPSEN shares last traded at $46.50, with a volume of 153 shares traded.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IPSEY shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Zacks Research upgraded shares of IPSEN to a “hold” rating in a report on Friday, May 29th. Finally, HC Wainwright started coverage on shares of IPSEN in a report on Friday, June 5th. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, IPSEN presently has a consensus rating of “Hold”.

IPSEN Trading Up 6.0%

The company has a fifty day moving average price of $47.53 and a two-hundred day moving average price of $43.40.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).